Abivax Announces Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (807M)
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing…
Abivax to Present Data on Obefazimod at Digestive Disease Week
Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Abivax Announces Full Exercise of Underwriters Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (637.5M)
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing…
